学術雑誌論文 Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis

Satoi, Sohei  ,  Fujii, Tsutomu  ,  Yanagimoto, Hiroaki  ,  Motoi, Fuyuhiko  ,  Kurata, Masanao  ,  Takahara, Naminatsu  ,  Yamada, Suguru  ,  Yamamoto, Tomohisa  ,  Mizuma, Masamichi  ,  Honda, Goro  ,  Isayama, Hiroyuki  ,  Unno, Michiaki  ,  Kodera, Yasuhiro  ,  Ishigami, Hironori  ,  Kon, Masanori

265 ( 2 )  , pp.397 - 401 , 2017-02 , Lippincott Williams & Wilkins, Inc.
ISSN:0003-4932
NII書誌ID(NCID):AA00533198
内容記述
OBJECTIVE:To evaluate the clinical efficacy and tolerability of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, "an oral fluoropyrimidine derivative containing tegafur, gimestat, and otastat potassium" in chemotherapy-naive pancreatic ductal adenocarcinoma (PDAC) patients with peritoneal metastasis.BACKGROUND:PDAC patients with peritoneal metastasis (peritoneal deposits and/or positive peritoneal cytology) have an extremely poor prognosis. An effective treatment strategy remains elusive.METHODS:Paclitaxel was administered i.v. at 50 mg/m and i.p. at 20 mg/m on days 1 and 8. S-1 was administered at 80 mg/m/d for 14 consecutive days, followed by 7 days of rest. The primary endpoint was 1-year overall survival (OS) rate. The secondary endpoints were antitumor effect and safety (UMIN000009446).RESULTS:Thirty-three patients who were pathologically diagnosed with the presence of peritoneal dissemination (n = 22) and/or positive peritoneal cytology (n = 11) without other organ metastasis were enrolled. The tumor was located at the pancreatic head in 7 patients and the body/tail in 26 patients. The median survival time was 16.3 (11.47-22.57) months, and the 1-year survival rate was 62%. The response rate and disease control rate in assessable patients were 36% and 82%, respectively. OS in 8 patients who underwent conversion surgery was significantly higher than that of nonsurgical patients (n = 25, P = 0.0062). Grade 3/4 hematologic toxicities occurred in 42% of the patients and nonhematologic adverse events in 18%. One patient died of thrombosis in the superior mesenteric artery.CONCLUSIONS:This regimen has shown promising clinical efficacy with acceptable tolerability in chemotherapy-naive PDAC patients with peritoneal metastasis.
本文を読む

https://tsukuba.repo.nii.ac.jp/?action=repository_action_common_download&item_id=40515&item_no=1&attribute_id=17&file_no=1

このアイテムのアクセス数:  回

その他の情報